OSTENIL4 TENDON for Treating Pain and Movement Problems in Patella, Peroneal, Medial Epicondylus Humeri, and Iliotibial Band Tendinopathy Effectiveness and Safety in Real-Life Clinical Use

What this Trial Is About

Researchers are evaluating the effectiveness and safety of OSTENIL4 TENDON in treating pain and restricted movement caused by four types of tendon disorders patella tendon, peroneal tendon, medial epicondylus humeri, and iliotibial band tendinopathy. This observational study takes place in real-life clinical settings and aims to provide more information on how this treatment works for these conditions when used as directed. Participants receive two injections of OSTENIL4 TENDON, which contains 2% sodium hyaluronate, given one week apart. The treatment targets specific tendon disorders, and its use follows the official instructions. The study monitors participants over several months after treatment to assess changes in pain and functional ability. During the study, participants report their pain levels and functional status at multiple points baseline, and weeks 1, 4, 12, and 24 after treatment ends. Researchers also evaluate tendon condition and collect safety data on any adverse events related to the treatment or device up to 24 weeks post-treatment. The primary measure is the change in pain intensity 3 months after treatment compared to before treatment. The total participation duration extends up to 24 weeks after treatment completion.

Effectiveness and Safety of OSTENIL® TENDON in the Treatment of Pain and Restricted Mobility in Tendon Disorders